Accept Cookies?
Print Page | Contact Us | Report Abuse | Sign In | Join Us
News & Press: News

Barcelona hosts 2nd meeting of m-RESIST

11 January 2017   (0 Comments)
Posted by: Heather Smith
Share |

 Barcelona hosts the second meeting of m-RESIST: new ways of care focused on patients with treatment-resistant schizophrenia

Coordinated by the Fundació TicSalut, the aim of the second meeting will be to close the current stage of identifying users’ needs

> Coordinated by the Fundació TicSalut, with the clinical leadership of the Hospital de Sant Pau and technological leadership of the Belgian organisation iMinds, the aim of the second meeting will be to close the current stage of identifying users’ needs, in order to start up a new stage of designing the new mobile health system for patients with treatment-resistant schizophrenia and their later development and integration.

> m-RESIST aims to develop a therapeutic programme that, with the support of mobile devices, actively involves patients with treatment-resistant schizophrenia and their carers, so that they are capable of self-managing their illness better.

Once the first stage of the projects has been completed, where mobile technology has been analysed in order to support new care methods and the users involved, Barcelona hosts the second meeting of m-RESIST, the first European project of mobile health for patients with treatment-resistant schizophrenia.

The European project m-RESIST, with Spain, Israel, Hungary, Finland, Belgium, Greece and Italy as the countries involved, and which began in January 2015, is moving towards a new stage. On the 2 and 3 of June the project heads will meet in Barcelona (in the Casa Convalescència building, in the historic complex of the Hospital de la Santa Creu i Sant Pau), with the task of drawing up conclusions about the work undertaken until now in order to identify the users’ needs and mark the starting point about what will be the design of the new system and the later development and integration.

The Fundació TicSalut, as a coordinating body of the consortium, works in the management of the project, which is a major challenge for patients, carers and professionals in the field of treatment-resistant schizophrenia. “During the first stage of the project a vision has been obtained about the needs and requisites which the new system will have to provide a response, in other words, how mobile technology can provide support to the new ways of care and the users involved”, explains Margarita Hospedales, leader of the project of the Fundació TicSalut.

The aim of the meeting will be to conclude the stage of drawing up requirements, based on the identification of the main problems that have been detected in each community (clinic, patients and carers). The user’s point of view is promoted and maintained throughout the life-cycle of the project. Now is the time to design the m-RESIST system, which is the next challenge to overcome”, concludes Hospedales.

m-Resist Project: objectives, funding and participation

The m-RESIST project (Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia) is a European project that aims to develop a therapeutic programme that draws on the support of mobile devices to actively involve patients with treatment-resistant schizophrenia and help their careers, making them capable of self-managing their own illness. m-RESIST will implement a model of analysis to move forward in understanding treatment-resistant schizophrenia and predict the behaviour of the illness.

m-RESIST has the potential of taking a step forward in the use of mobile technologies and actively involve the patients in self-managing their condition, with the aim of improving the patient’s adherence to the treatment”, remarks Jesús Berdún, project manager of the Fundació TicSalut involved in the project. He adds, “for the Fundació TicSalut , this is a major opportunity to transfer the know-how produced in the project to the suppliers and professionals of local health systems” .

m-Resist has received funding from the European Union Horizon 2020 research and innovation programme by virtue of subsidy agreement number 643.552, with a budget of four million euros. Seven European countries have taken part in this project and a total of twelve entities from both the public and private sectors, hospitals, universities and companies.

Participants of the project:

Fundació TicSalut (Spain), Hospital de la Santa Creu i Sant Pau (Spain),  Parc Sanitari Sant Joan de déu (Spain), The Gertner Institute for Epidemiology & Health Policy Research (Israel), Oulun Yliopisto (Finland), iMinds VZW (Belgium), IBM Global Services España SA (Spain), Athens Technology Center SA (Greece), Semmelweis Egyetem (Hungary), Agència De Qualitat I Avaluació Sanitàries De Catalunya (Spain), AB.ACUS SRL (Italy) and Institute Of Communication And Computer Systems (Greece).